The supplementary material of"Gastrointestinal manifestations in pediatric IgA vasculitis: associations with disease activity and outcomes"
Description
This material contains the supplementary tables and figures:Supplementary Figure 1. The flowchart of patient selection; Supplementary Figure 2. a. The age distribution of IgAV patients; b. The monthly distribution of all IgAV patients; c. The monthly distribution of IgAV patients by years; d. The monthly variations in the average annual number of cases before, during and after the pandemic; Supplementary Figure 3. The distribution of BVAS between GI manifestations after purpura and GI manifestation prior to purpura. (ns p>0.05); Supplementary Figure 4. Representative renal pathological images obtained from 79 IgAVN patients. A-H: Class-II (31 cases), -IIIa (12 cases), -IIIb (33 cases) and -Ⅳ (1 case), light microscopy, glomerulus (A-D: hematoxylin and eosin stain, E-H: Periodic Schiff-Methenamine staining, original magnification × 400). I-N: The highest intensity of Immune complex deposits (I: 4+ IgA staining in 5 patients, J: 3+ IgG staining in 1 case, K: 3+ IgM staining in 3 cases, L: 3+ C3 staining in 9 cases, M: 3+ kappa staining in 24 cases, N: 2+ lambda staining in 23 cases, original magnification × 400); Supplementary Table 1. Multivariate logistic regression analysis of factors related to recurrence/relapse; Supplementary Table 2. ISKDC classifications and immunofluorescence features in GI and non-GI groups
Files
Steps to reproduce
2236 IgAV children were identified from January 2015 to December 2023.The diagnostic criteria of IgAV were referred to the 2008EULAR/PRINTO/PRES recommendations.2 Severe abdominal symptoms were defined as severe abdominal pain limiting mobility and requiring bed rest, melena/hematochezia, and/or GI complications. Renal pathological features were graded according to the International Study of Kidney Disease in Children classification(ISKDC). Disease activity was assessed by the Birmingham Vasculitis Activity Score, version 3(BVAS v3). Relapse/recurrence was defined when a patient previously diagnosed with IgAV and asymptomatic for at least 2 weeks, presented again a new episode of cutaneous lesions.